Abstract-Obesity, hypertension, cardiovascular disease, and inflammation are closely associated with the rising incidence of diabetes mellitus. One pharmacological target that may have significant potential to lower the risk of obesity-related diseases is the angiotensin type 1 receptor (AT1R). We examined the hypothesis that the AT1R blocker valsartan reduces the metabolic consequences and inflammatory effects of a high-fat (Western) diet in mice. C57BL/6J mice were treated by oral gavage with 10 mg/kg per day of valsartan or vehicle and placed on either a standard chow or Western diet for 12 weeks. Western diet-fed mice given valsartan had improved glucose tolerance, reduced fasting blood glucose levels, and reduced serum insulin levels compared with mice fed a Western diet alone. Valsartan treatment also blocked Western diet-induced increases in serum levels of the proinflammatory cytokines interferon-␥ and monocyte chemotactic protein 1. In the pancreatic islets, valsartan enhanced mitochondrial function and prevented Western diet-induced decreases in glucose-stimulated insulin secretion. In adipose tissue, valsartan reduced Western dietinduced macrophage infiltration and expression of macrophage-derived monocyte chemotactic protein 1. In isolated adipocytes, valsartan treatment blocked or attenuated Western diet-induced changes in expression of several key inflammatory signals: interleukin 12p40, interleukin 12p35, tumor necrosis factor-␣, interferon-␥, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase, and AT1R. Our findings indicate that AT1R blockade with valsartan attenuated several deleterious effects of the Western diet at the systemic and local levels in islets and adipose tissue. This study suggests that AT1R blockers provide additional therapeutic benefits in the metabolic syndrome and other obesity-related disorders beyond lowering blood pressure. Key Words: valsartan Ⅲ angiotensin type 1 receptor Ⅲ inflammation Ⅲ adipose tissue Ⅲ macrophages Ⅲ islets O besity is a metabolic disorder characterized by chronic inflammation and dyslipidemia and is a strong predictor for the development of hypertension, diabetes mellitus, and cardiovascular disease. One potential pharmacological target for treating obesity-related metabolic disorders is angiotensin II, a regulator of cardiovascular homeostasis (reviewed in Reference 1). Dysregulated angiotensin activity leads to hypertension and other cardiovascular complications. Specific inhibitors, such as the angiotensin type 1 receptor (AT1R) blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors, have implicated this pathway also in the development of metabolic diseases, like obesity and type 2 diabetes mellitus. A meta-analysis of clinical trials with these inhibitors revealed an overall 25% reduction in new-onset diabetes mellitus. 2 In addition, ARB treatment decreases fat cell volume and fat accumulation and improves differentiation of adipocytes, which is associated with a more insulin-sensitive phenotype. [3][4][5][6] Thus, targeting angiotensin II may be a viable strategy in the treatment of the metabolic syndrome, type 2 diabetes mellitus, and other obesity-related disorders.
O besity is a metabolic disorder characterized by chronic inflammation and dyslipidemia and is a strong predictor for the development of hypertension, diabetes mellitus, and cardiovascular disease. One potential pharmacological target for treating obesity-related metabolic disorders is angiotensin II, a regulator of cardiovascular homeostasis (reviewed in Reference 1). Dysregulated angiotensin activity leads to hypertension and other cardiovascular complications. Specific inhibitors, such as the angiotensin type 1 receptor (AT1R) blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors, have implicated this pathway also in the development of metabolic diseases, like obesity and type 2 diabetes mellitus. A meta-analysis of clinical trials with these inhibitors revealed an overall 25% reduction in new-onset diabetes mellitus. 2 In addition, ARB treatment decreases fat cell volume and fat accumulation and improves differentiation of adipocytes, which is associated with a more insulin-sensitive phenotype. [3] [4] [5] [6] Thus, targeting angiotensin II may be a viable strategy in the treatment of the metabolic syndrome, type 2 diabetes mellitus, and other obesity-related disorders.
Angiotensin II is part of the renin-angiotensin system (RAS) and acts as a vasoconstrictor of blood vessels, thereby regulating blood pressure, vascular tone, and fluid and electrolyte balance. Angiotensin II is also proinflammatory in blood vessels, causing increased reactive oxygen species release, increased nuclear factor-B nuclear translocation and subsequent proinflammatory cytokine transcription, and reduced endothelial NO synthase activity (reviewed in Reference 7). These proinflammatory pathways can be blocked by ARBs. 8 In spite of clinical support for ARB and ACE inhibitor treatment in reducing diabetes mellitus onset, the protection offered to pancreatic islets and adipocytes remains unclear. Local RAS have been identified in both pancreatic and adipose tissues and may play roles in the progression of the metabolic syndrome (reviewed in References 9 and 10). To concurrently address the in vivo effects of ARB administration on islets and adipose tissue, we orally administered valsartan to C57BL/6J mice fed either a chow or high-fat (Western) diet. We evaluated the drug's effects on metabolism, pancreatic islet and adipocyte function, and macrophage infiltration into adipose tissue and ensuing systemic inflammation. The results suggest that valsartan ameliorates the damaging effects of high-fat feeding on pancreatic ␤-cell function and adipose tissue inflammation. Our study is the first to address the potential of ARB protection of both islets and adipose tissue in vivo in a high-fat diet mouse model.
Methods
Male C57BL/6J mice were treated daily by oral gavage with 10 mg/kg per day of valsartan or vehicle and placed on either a standard chow or Western diet for 12 weeks beginning at 6 to 8 weeks of age, as reported previously. 11 Measurements of glucose and insulin tolerance, body weight, and fasting blood glucose (BG) were made before termination. Pancreas, fat, and serum were then collected for additional studies. Methodologic details are provided in the online Data Supplement (available at http://hyper.ahajournals.org). All of the experiments were performed in accordance with an animal study protocol approved by the University of Virginia Institutional Animal Care and Use Committee.
Results

Effects of Valsartan and Western Diet on Body Weight and BG
C57BL/6J mice were placed either on a chow or Western (west) diet for 12 weeks and treated orally with 10 mg/kg per day of valsartan (V) or water vehicle. Body weight and BG were measured weekly. As shown in Figure 1A , the Western diet caused significantly greater weight gain (including epididymal fat pad weight gain; see Figure 5B ) by the end of the 12-week trial for both valsartan-treated and vehicle-treated mice. Neither body weights nor weight gains differed between west and westϩV groups. Valsartan, thus, does not impact diet-induced weight gain or enlargement of adipose tissue.
Weekly BG measurements did not differ among treatment groups at any point throughout the 12-week trial and remained Ͻ250 mg/dL in all of the treatment groups, indicating no incidence of diabetes mellitus (mean BG at last reading: chow, 168Ϯ4; chowϩV, 169Ϯ7; west, 169Ϯ6; westϩV, 174Ϯ5 mg/dL). However, as shown in Figure 1B , overnight fasting BG in mice at 10 weeks on the diet showed significant increases in the west group as compared with the chow-fed groups. Nonfasted insulin levels obtained at the termination of the study were substantially increased by the high-fat diet ( Figure 1C ). This effect was attenuated by valsartan. Consistent with increased and attenuated insulin secretion, respectively, islet hyperplasia was present in the west group but was absent in the westϩV group ( Figure S1 ). Furthermore, the proportion of insulin-stained ␤-cells in the islets was significantly decreased in the west group and preserved with valsartan treatment ( Figure S1 ).
Glucose and Insulin Tolerance
Mice were subjected to a glucose tolerance test and insulin tolerance test at weeks 10 and 11, respectively. As shown in Figure 2 , chow and chowϩV groups displayed similar responses to the intraperitoneal glucose challenge. The west group had higher fasting BG before the glucose bolus (PϽ0.05; see also Figure 1B ), did not respond as quickly, and glucose remained elevated when compared with chow-fed groups (PϽ0.01), suggesting that the west group has impaired glucose tolerance (Figure 2 ). The westϩV group showed a significant improvement in glucose tolerance compared with the west group but did not fully normalize to the level of controls (Figure 2) . The insulin tolerance test indi- cated slightly better insulin sensitivity in the chowϩV mice (see Figure S2 ).
Valsartan Reduces Levels of Serum Cytokines
We obtained blood serum measurements for 32 circulating cytokines at the termination of the 12-week trial using a Luminex system (see online Data Supplement for list of cytokines, at http://hyper.ahajournals.org). As shown in Table  1 , interferon (IFN) -␥ and monocyte chemotactic protein (MCP) 1, both key products of obesity-mediated inflammation, were significantly elevated in the west group compared with the chow group. This effect was reversed in the westϩV group. In addition, macrophage inflammatory protein 1␤ and regulated on activation, normal T expressed and secreted were both reduced in the westϩV group compared with the chow and the west groups (Table 1) . No significant differences were observed for the other cytokines tested.
Valsartan Improves Glucose-Stimulated Insulin Secretion
Isolated islets were assessed for physiological function by measuring basal insulin secretion (3 mmol/L of glucose) followed by glucose-stimulated insulin secretion (28 mmol/L of glucose). As shown in Figure 3 , islets from both west and westϩV mice showed an increase in basal and glucosestimulated insulin secretion (28 mmol/L) compared with chow-fed groups. Mice in the westϩV group also showed enhanced insulin secretion in 28 mmol/L of glucose compared with mice fed a western diet alone ( Figure 3 ). The ratio of stimulated:basal glucose (glucose stimulation index) was marginally reduced for the west group compared with the other treatment groups. These data suggest that valsartan tends to enhance glucose-stimulated insulin secretion in the context of a high-fat diet.
Valsartan Enhances Islet Mitochondrial Activity
We next examined islet mitochondrial activity because the angiotensin system may affect cell metabolism (reviewed in Reference 12) . As shown in Figure 4A , increases in mitochondrial membrane potential were observed among islets from mice treated with valsartan. This result was supported by separate measurements of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] ( Figure 4B ), a known product of mitochondrial activity. Thus, valsartan clearly has a stimulatory effect on the mitochondrial gradient that drives ATP production and increases the byproducts of mitochondrial activity.
Islet Gene Expression
We examined islet expression of several key proinflammatory genes (IFN-␥, tumor necrosis factor [TNF]-␣, MCP-1, IL-12p35, and IL-12p40). The 12-week Western diet caused an increase only in IFN-␥ expression (6.13-fold) that approached significance (Pϭ0.07) and that was reduced by valsartan treatment (0.58-fold; Pϭ0.06).
Valsartan Reduces Macrophage Infiltration Into Adipose Tissue
To investigate anti-inflammatory effects of valsartan, adipose tissue (epididymal fat pads) was collected and processed to isolate stromal vascular cells for fluorescence-activated cell sorter analysis. As shown in Figure 5A , macrophage content detected by both F4/80 and CD11b antibodies in the CD45-positive gate was nearly double in the west group compared with the chow group. However, macrophage numbers were significantly lower in the westϩV group compared with the west group. As shown in Figure 5B , fat pad weights were much greater for all of the mice fed the western diet, and valsartan treatment did not reduce fat pad weight. Adipocyte size was significantly increased with Western diet, and this effect was ameliorated by valsartan ( Figures 5C and S3 ). These findings suggest that valsartan reduces the inflammatory response caused by Western diet-induced changes in adipose tissue. The Ϸ2-fold reduction in adipocyte size in the presence of dramatically increased fat pad weight in the westϩV group suggests that valsartan increases total adipocyte number in adipose tissue.
Effects of Valsartan on Gene Expression in Visceral Adipose Tissue and Isolated Adipocytes
We also investigated the possible effects of valsartan on the expression of key proinflammatory genes in visceral fat. As shown in Table 2 , a substantial increase in MCP-1 expression, a key component in macrophage signaling, was seen in epididymal fat tissue from the west group. The increase was attenuated by valsartan treatment. TNF-␣ and IL-6 showed a similar trend as MCP-1, but changes were not significant (Table 2) . Adiponectin, an anti-inflammatory adipocytederived factor, showed reduced expression levels among mice on the Western diet (Table 2) ; valsartan did not affect adiponectin expression. Increased expression of IL-12p40 was observed in the west group when compared with the chow group (Table 2) . Valsartan increased IL-12p40 in the chow and west groups to similar levels. We also examined differences in gene expression in isolated adipocytes. Although some findings were similar to those reported for whole fat tissue, some of the differences were more pronounced, and new changes were seen in isolated adipocytes. As shown in Table 3 , the west group showed significant upregulation of IL-12p35 and IL-12p40, whereas valsartan downregulated these proinflammatory cytokines in the chow and west groups. The Western diet also upregulated TNF-␣, IFN-␥, and the anti-inflammatory enzyme platelet 12-LO, implicated in angiotensin regulation (Table 3 ; see discussion for 12-lipoxygenase [12-LO]); these effects were prevented in the westϩV group. Adiponectin was significantly downregulated in the west group (Table 3) ; however, unlike in whole fat tissue, valsartan reversed the effects of the Western diet in isolated adipocytes. The Western diet did not significantly upregulate toll-like receptor 4, MCP-1, or IL-6 (Table 3) , although valsartan treatment reduced expression for each of these genes compared with chow controls to some degree. In addition, expression of the extracellular matrix protein collagen 6 and inducible NO synthase, both upregulated in obese rodent models in an inflammation-dependent manner, 13, 14 are induced by the Western diet and decreased with valsartan treatment (Table  3) . Finally, the AT1R was significantly upregulated by the Western diet, and the effect was abrogated with valsartan treatment (Table 3) . Taken together, these data suggest that Western diet-induced obesity substantially activates inflammation in adipocytes, and valsartan treatment attenuated or prevented it (see Figure S4 ).
Discussion
Our study provides evidence that treatment of Western diet-fed mice with the AT1R blocker valsartan significantly reduces the deleterious effects of a high-fat intake. Noticeably, Western diet-fed mice treated with valsartan exhibited improved glucose tolerance, improved insulin sensitivity (as indicated by lower serum insulin), reduced signs of visceral adipose tissue inflammation and macrophage infiltration, and improved pancreatic islet function compared with mice fed a Western diet alone. These data suggest that the RAS plays a key role in modulating metabolism and the inflammatory response in response to a high-fat diet (see Figure S4 ). When challenged with a high-fat diet, free fatty acids and inflammatory mediators are secreted by adipocytes and stromal inflammatory cells in the adipose tissue. These factors are released into the circulation to exert systemic effects. 15 Elevated MCP-1 is associated with obesity, diabetes mellitus, and cardiovascular disease. MCP-1, the strongest known chemotactic factor for monocytes, is responsible for macrophage infiltration into the adipose tissue, leading to further cytokine expression, such as TNF-␣, and thereby promoting inflammation. MCP-1 expression is increased by angiotensin II and reduced by RAS blockade. 16, 17 Consistent with these earlier findings, we observed that, in the context of a high-fat diet, valsartan reduced systemic and local adipose tissue MCP-1 levels and macrophage infiltration into the visceral adipose tissue. This may be one key mechanism by which valsartan reduces adipose tissue inflammation. We observed that MCP-1 was upregulated by a Western diet in total adipose tissue and not in isolated adipocytes, whereas proinflammatory cytokines were upregulated in isolated adipocytes and not in total adipose tissue. This is consistent with reported observations that angiotensin II induces MCP-1 expression in preadipocytes and the macrophage-containing stromal vascular pool and not in adipocytes, whereas MCP-1 induces the expression of proinflammatory cytokines in adipocytes. 18 -20 Central obesity correlates with an increased risk of developing type 2 diabetes mellitus. Adipose tissue dysfunction leads to increased release of proinflammatory mediators, which, in turn, impair insulin signaling and pancreatic ␤-cell function. For example, MCP-1, IFN-␥, IL-6, IL-12, and inducible NO synthase act systemically to impair whole body insulin sensitivity, 21 and acute expression of a dominantnegative MCP-1 in wild-type C57BL/6J mice fed a high-fat diet or db/db mice can reverse insulin resistance. 22 Indeed, in our study, the mice fed a Western diet exhibited increased MCP-1, IFN-␥, IL-12, and inducible NO synthase expression in serum and adipose tissue and impaired glucose tolerance and insulin sensitivity, and these changes were normalized by valsartan treatment. Adiponectin is an adipocyte-specific adipokine that improves insulin sensitivity by increasing energy expenditure and fatty acid oxidation. 23 However, MCP-1 activation can decrease adiponectin expression. 23 Type 2 diabetics often exhibit decreased levels of adiponectin, and insulin sensitivity is improved by adiponectin therapy. 24 Treatment of hypertensive patients with ARBs leads to increased serum adiponectin levels. 25, 26 We observed that treatment of Western diet-fed mice with valsartan ameliorated the diet-induced decrease in adiponectin in adipocytes, providing further support for a therapeutic role of AT1R blockade in restoring insulin sensitivity.
Angiotensin II primarily acts via the G protein-coupled transmembrane receptor AT1R (reviewed in References 1 and 7). In our study, we observed that AT1R expression in adipocytes, which express all of the components of the RAS, 27 was significantly upregulated when mice were fed a Western diet, and this effect was reversed with valsartan administration. This is the first report that a high-fat diet leads to increased AT1R expression in adipocytes and that this can be prevented by ARB treatment.
High-fat diet-induced adipocyte hypertrophy leads to fibrosis of adipose tissue, which promotes shear stress and inflammation. 13 Consistent with this, we observed that collagen 6 is upregulated in adipocytes from Western diet-fed mice, and this is ameliorated by valsartan treatment. Studies using valsartan have demonstrated decreases in adipocyte size and total visceral fat mass in rodents. 3, 6, 28 We observed a decrease in adipocyte size when Western diet-fed mice are treated with valsartan. This is consistent with the idea that AT1R blockade improves adipocyte function by promoting the development of smaller and more metabolically efficient adipocytes. No changes were observed in body weight or epididymal fat pad weight between the west and westϩV groups in our study. This may be explained by differences in the dosage and duration of valsartan treatment in the previous studies, suggesting that longer valsartan treatment in our mice may eventually decrease adipose tissue weight. This is of clinical relevance, because short-term valsartan administration in humans did not improve ␤-cell function and insulin responsiveness. Thus, longer therapeutic ARB treatment in humans may be needed for metabolic improvement. 29 The existence of a local RAS in the pancreatic islets is gaining increasing recognition, and this RAS is induced by physiological and pathophysiological stimuli (reviewed in Reference 9). The pancreatic islet RAS regulates endocrine and exocrine functions relevant to the metabolic syndrome, such as local islet blood flow, islet ␤-cell proinsulin biogenesis, glucose-stimulated insulin release, mitochondrial function, and pancreatic duct and acinar cell secretion (reviewed in References 9 and 12). Angiotensin II impairs islet blood flow and can directly impair glucose-mediated insulin release. 30 It also promotes mitochondrial oxidant release leading to decreased energy metabolism in the islets. Dysfunctional mitochondria contribute to the pathophysiology of diseases, such as hypertension, cardiovascular disease, and diabetes mellitus (reviewed in Reference 12) . In support of a role for the islet RAS in mediating ␤-cell function, we observed that valsartan decreased islet hyperplasia, enhanced mitochondrial activity, decreased IFN-␥ expression, and mildly enhanced insulin secretion in islets. Similarly, islets from the obesity-induced type 2 diabetes db/db mouse model exhibited upregulation of RAS components and decreased ␤-cell function, and treatment with the ARB losartan improved glucose-induced insulin release from these islets. 31 This improvement may occur in part through reduction of the local islet inflammatory response in the presence of ARB. 32, 33 However, it is possible that ARB effects in islets may be secondary to reduced inflammation in visceral adipose tissue and reduced systemic inflammation. This is consistent with the lack of altered gene expression of components of the pancreatic RAS (data not shown).
Finally, our data indicate that ARB administration may target members of the fatty-acid metabolizing 12-LO family, because we observed decreased expression of the platelet form of 12-LO in adipocytes of valsartan-treated mice. We reported recently that 12-LO products promote an inflammatory response and impair insulin signaling in adipocytes. 34 Moreover, 12-LO activation plays a significant role in promoting ␤-cell toxicity, inflammation, and atherosclerosis 11 ; (reviewed in Reference 35). The major arachidonic acid metabolite of 12-LO, 12(S)-hydroxyeicosatetraenoic acid, enhances AT1R expression in type 2 diabetic rat glomeruli 36 and is secreted in patient urine during the early diabetic process (reviewed in Reference 35) . Angiotensin II increases expression of 12(S)-hydroxyeicosatetraenoic acid in porcine vascular smooth muscle cells and fails to elicit vascular responses in 12-LO-deficient mice (reviewed in References 35 and 37). The ARB drugs valsartan and losartan decrease 12(S)-hydroxyeicosatetraenoic acid expression in streptozotocin-induced diabetic mice and 12-LO expression in obese Zucker rat renal cortical tissue, respectively. 38, 39 Thus, AT1R may be a regulator of 12-LO activity and is also regulated by 12-LO activity. Establishing the role that 12-LO plays in mediating RAS activity and ensuing complications will require additional studies.
Perspectives
In summary, AT1R blockade with valsartan significantly ameliorates several detrimental effects of a high-fat diet in mice: it reduces the inflammatory response, improves glucose tolerance, and offers protection for islet and adipose tissue (see Figure S4 ). Our study is unique in that we concurrently examined 2 key tissues targeted in the progression of the metabolic syndrome: type 2 diabetes mellitus and other obesity-related disorders. Our results indicate that angiotensin II blockade may be an effective therapeutic strategy for the treatment of these diseases.
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